David Leslie Paterson

Evidence of International Standing • 548 career publications (h-index 131; 92,841 citations) – most cited Infectious Diseases physician in Australia and Singapore • Australia’s research field leader – communicable diseases – 2020 and 2021 (https://specialreports.theaustralian.com.au/1540291/18/) • Clarivate Highly Cited Researcher annually from 2015 to 2022 • Ranked number 2 in the world in the field of “Multiple Drug Resistance”; (expertscape.com) • Member, 10 person Scientific Advisory Board for AMR Action Fund ($1 billion fund for investing in new antibiotics) • Member, WHO Advisory Group on the Bacterial Priority Pathogen List • Member, Steering Committee, Antibiotic Resistance Leadership Group (NIH funded; only non-US member) • Fellow, European Society for Clinical Microbiology and Infectious Diseases • Member, European Society for Clinical Microbiology and Infectious Diseases International Affairs Committee (2015-2020) • Founder, MERINO trial network for investigator-initiated clinical trials on antibiotic treatment of bloodstream infection (40 hospitals in 15 countries) • NIH and CDC grant recipient • Editor, The Use of Antibiotics (2010 and 2015 editions) • Invited lecturer in 30 countries worldwide • Grand Rounds Facilitator. American Society for Microbiology ICAAC Meeting, 2010-2016. • Elected, Academy of Master Educators, University of Pittsburgh School of Medicine (2006) • Winner, Excellence in Education (Best Lecturer of first year medical students), University of Pittsburgh School of Medicine (2004, 2005, 2006, 2007) • Three mentees are now Professors of Medicine (Yohei Doi, Fernanda Silveira and Anton Peleg)